To explore whether central lymph node ratio (LNR) can be used to predict lateral lymph node metastasis (LLNM) in pediatric patients with differentiated thyroid carcinoma (DTC) and to construct a predictive model for clinical decision-making.
Key Findings:
Central LNR threshold of 0.4 predicts LLNM with a sensitivity of 90.0% and specificity of 76.0%.
Multivariate analysis identified central LNR, bilaterality, and ≥4 metastatic central nodes as independent predictors of LLNM.
Interpretation:
An LNR ≥0.4 is a significant indicator for identifying high-risk pediatric DTC patients, which can aid in making informed surgical decisions.
Limitations:
Retrospective design may introduce selection bias.
Single-center study limits generalizability of findings.
The time frame of the study may affect the relevance of the findings.
Conclusion:
Central LNR, bilaterality, and ≥4 metastatic central lymph nodes are critical predictors for LLNM in pediatric DTC, supporting tailored surgical approaches that can improve patient outcomes.
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
